BOJ keeps interest rates flat, but flags rate hikes on rising inflation, GDP
GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ: SLXN), a micro-cap biotechnology firm with a market capitalization of $9.93 million focused on RNA interference (RNAi) therapies, has announced an expanded development plan for its siRNA candidate, SIL204, targeting KRAS-driven cancers. According to InvestingPro data, the company’s stock has experienced significant volatility, declining 98.83% over the past year. The dual-route strategy, combining intratumoral and systemic administration, aims to address both primary tumors and metastases, particularly in pancreatic cancer.
The company’s decision to broaden its development approach follows promising preclinical results, showing significant inhibition of tumor growth in pancreatic cancer models. Silexion’s CEO, Ilan Hadar, stated that the plan reflects their commitment to tackling the complexities of KRAS-driven cancers, which are known for high mortality rates and limited treatment options. Despite the challenging market conditions, analysts maintain a $5 price target for the stock, suggesting potential upside from current levels of $1.18.
Silexion has outlined a clear development pathway for SIL204, with additional studies planned throughout 2025. Regulatory submissions are anticipated in the second half of 2025 to the Israel Ministry of Health, and in the first half of 2026 to the European Union. These steps are preparatory for initiating human trials in the first half of 2026, focusing on advanced localized KRAS-driven pancreatic cancer.
The company’s first-generation product, siG12DLoder, has already demonstrated an overall survival benefit in Phase 2 clinical trials. Building on this, recent studies have shown SIL204’s potential in reducing metastases and maintaining drug levels in secondary tumors for extended periods after a single subcutaneous administration.
Silexion will present its expanded development plan and recent preclinical findings at the Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference today. The company continues to develop RNAi therapies for solid tumors driven by KRAS mutations, with LODER™ showing promising results in non-resectable pancreatic cancer.
This news is based on a press release statement by Silexion Therapeutics and contains forward-looking statements that involve risks and uncertainties. The company’s future plans and ability to achieve its goals depend on various factors, including the success of ongoing preclinical studies and the regulatory environment. InvestingPro analysis indicates a WEAK financial health score of 1.09, with additional insights and metrics available to subscribers. The company’s next earnings report is scheduled for June 13, 2025. Silexion has not undertaken any obligation to revise forward-looking statements as of the date they are made.
In other recent news, Silexion Therapeutics Corp announced significant preclinical results for their drug candidate SIL-204, targeting KRAS-driven cancers. The company reported that SIL-204 substantially reduced tumor growth in pancreatic cancer models, decreasing tumor growth by approximately 50% after 30 days, with half of the tumors showing complete necrosis. Additionally, Silexion Therapeutics disclosed that a single administration of SIL-204 maintained effective drug concentrations in rat plasma and tissues for over 56 days. In another development, the company has entered into an agreement to retire a convertible promissory note held by EarlyBirdCapital, Inc. The note, originally set to mature in December 2025, was retired through a $400,000 cash payment and the issuance of 277,777 ordinary shares. This strategic move is part of Silexion’s financial management efforts. The shares issued are part of a previously effective registration statement on Form S-1. The details of the agreement were outlined in a recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.